Abstract
Tiotropium Respimat® Soft Mist™ inhaler (Spiriva® Respimat®) is indicated as a maintenance bronchodilator to relieve the symptoms of patients with chronic obstructive pulmonary disease (COPD) in the EU. The delivered drug dose is independent of inspiratory effort and the prolonged duration of the aerosol cloud should make the co-ordination of actuation and inhalation easier. In patients with COPD, tiotropium Respimat® improved lung function, COPD exacerbations, health-related quality of life and dyspnoea, and was generally well tolerated. Relative to administration of tiotropium via the HandiHaler®, administration of the drug via the Respimat® Soft Mist™ inhaler improves lung deposition of the drug (allowing a lower nominal dose to be used), is at least as effective, and has a similar tolerability profile.
Similar content being viewed by others
References
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2014. Bethesda: Global Initiative for Chronic Obstructive Lung Disease; 2014.
Human medicines: European public assessment reports. London: European Medicines Agency; 2014.
Barnes PJ. The pharmacological properties of tiotropium. Chest. 2000;117(2 Suppl):63S–6S.
Tautermann CS, Kiechle T, Seeliger D, et al. Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor. J Med Chem. 2013;56(21):8746–56.
Spiriva (tiotropium) Respimat 2.5 micrograms, inhalation solution: EU summary of product characteristics. Ingelheim am Rhein: Boehringer Ingelheim International GmbH; 2014.
Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. Drugs. 2012;72(2):273–300.
Dalby R, Spallek M, Voshaar T. A review of the development of Respimat® Soft Mist™ Inhaler. Int J Pharm. 2004;283(1–2):1–9.
Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12(Suppl 1):S19–24.
Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat® Soft Mist™ inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–82.
Pitcairn G, Reader S, Pavia D, et al. Deposition of corticosteroid aerosol in the human lung by Respimat® Soft Mist™ inhaler compared to deposition by metered dose inhaler or by Turbuhaler® dry powder inhaler. J Aerosol Med. 2005;18(3):264–72.
Newman SP, Steed KP, Reader SJ, et al. Efficient delivery to the lungs of flunisolide aerosol from a new portable hand-held multidose nebulizer. J Pharm Sci. 1996;85(9):960–4.
Hohlfeld JM, Sharma A, van Noord JA, et al. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol. 2014;54(4):405–14.
Newman SP, Steed KP, Reader SJ, et al. An in vitro study to assess facial and ocular deposition from Respimat® Soft Mist™ inhaler. J Aerosol Med. 2007;20(1):7–12.
Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat® Soft Mist Inhaler™ or HandiHaler® in COPD patients. Int J Chron Obstruct Pulm Dis. 2007;2(4):559–65.
van Noord JA, Cornelissen PJG, Aumann J-L, et al. The efficacy of tiotropium administered via Respimat® Soft Mist Inhaler™ or HandiHaler® in COPD patients. Respir Med. 2009;103(1):22–9.
Voshaar T, Lapidus R, Maleki-Yazdi R, et al. A randomized study of tiotropium Respimat® Soft Mist™ inhaler vs. ipratropium pMDI in COPD. Respir Med. 2008;102(1):32–41.
Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 μg via Respimat and 18 μg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med. 2010;104(2):228–36.
Bateman E, Singh D, Smith D, et al. Efficacy and safety of tiotropium Respimat® SMI in COPD in two 1-year randomized studies. Int J Chron Obstruct Pulm Dis. 2010;5:197–208.
Bateman ED, Tashkin D, Siafakas N, et al. A 1-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460–72.
Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–501.
Tashkin D, Metzdorf N, Hallmann C, et al. Safety of tiotropium in renally impaired patients [abstract no. P923 plus poster]. In: European Respiratory Society International Congress. 2014.
Feifel U, Wallenstein G, Rominger K-L, et al. Pharmacokinetics and tolerability (study 1) with particular reference to ocular safety (study 2) of tiotropium Respimat® Soft Mist Inhaler™: findings from two dose-ranging studies in healthy men. Int J Chron Obstruct Pulm Dis. 2008;3(3):397–403.
Calverley P, Könen-Bergmann M, Metzdorf N, et al. Tiotropium Respimat®: comparison of bronchodilator efficacy of 5- and 2.5-μg doses [abstract no. P924 plus poster]. In: European Respiratory Society International Congress. 2014.
Rau-Berger H, Mitfessel H, Glaab T. Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulm Dis. 2010;5:367–73.
Hodder R, Pavia D, Lee A, et al. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD. Int J Chron Obstruct Pulm Dis. 2011;6:245–51.
Mathioudakis AG, Chatzimavridou-Grigoriadou V, Evangelopoulou E, et al. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent? Pulm Pharmacol Ther. 2014;28(2):91–7.
Halpin D, Dahl R, Hallmann C, et al. Tiotropium Handihaler® and Respimat® in COPD: a safety analysis on pooled data [abstract]. In: American Thoracic Society International Conference. 2014.
Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.
Pharmacovigilance Risk Assessment Committee (PRAC): minutes of the meeting on 5–8 May 2014. London: European Medicines Agency; 2014.
Bateman ED. Improving inhaler use in COPD and the role of patient preference. Eur Respir Rev. 2005;14(96):85–8.
Anderson P. Use of Respimat® Soft Mist™ Inhaler in COPD patients. Int J Chron Obstruct Pulm Dis. 2006;1(3):251–9.
Fink JB, Colice GL, Hodder R. Inhaler devices for patients with COPD. COPD. 2013;10(4):523–35.
Asakura Y, Nishimura N, Maezawa K, et al. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv. 2013;26(1):41–5.
Keating GM. Tiotropium Respimat® Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014;74(15):1801–16.
Acknowledgments
The manuscript was reviewed by: S.A. Antoniu, University of Medicine and Pharmacy Grigore T Popa Iasi, Department of Interdisciplinary-Pallistive Care Nursing, Iasi, Romania; C. Incorvaia, Pulmonary Rehabilitation Unit, Instuti Clinici de Perfezionamento, Presidio Ospedaliero CTO, Milan, Italy; R. Janknegt, Orbis Medical Centre, Sittard-Geleen, The Netherlands; R.B. Shah, Department of Pharmacology, GMERS Medical College and Hospital, Gandhinagar, Gujarat, India
Disclosure
This article was adapted from Drugs 2014;74(15):1801–16 by salaried employees of Adis/Springer [34]. The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lyseng-Williamson, K.A., Keating, G.M. Tiotropium Respimat® Soft Mist™ inhaler: a guide to its use in chronic obstructive pulmonary disease (COPD) in the EU. Drugs Ther Perspect 31, 39–44 (2015). https://doi.org/10.1007/s40267-014-0181-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-014-0181-x